Last reviewed · How we verify

Aldactone — Competitive Intelligence Brief

Aldactone (Spironolactone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium-sparing diuretic, aldosterone antagonist. Area: Metabolic.

marketed Potassium-sparing diuretic, aldosterone antagonist Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Aldactone (Spironolactone) — Pfizer Inc.. Aldosterone antagonist causing increased sodium and water excretion while retaining potassium.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Aldactone TARGET Spironolactone Pfizer Inc. marketed Potassium-sparing diuretic, aldosterone antagonist Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Potassium-sparing diuretic, aldosterone antagonist class)

  1. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aldactone — Competitive Intelligence Brief. https://druglandscape.com/ci/aldactone. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: